Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087266 | 1.00 | CTSL (0.38) | CTSLPOLBCTSSNAAACTSB | |
| SCHEMBL15087265 | 1.00 | CTSL (0.38) | CTSLPOLBCTSSNAAACTSB | |
| SCHEMBL15087270 | 0.94 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087272 | 0.94 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087273 | 0.94 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087231 | 0.90 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087224 | 0.90 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087228 | 0.90 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087232 | 0.90 | CTSL (0.39) | CTSLCTSSNAAACTSBCTSK | |
| SCHEMBL15087252 | 0.89 | CTSL (0.38) | CTSLCTSSNAAACTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175044-B2 | Derivatives of glyco-CF2-serine and glyco-CF2-threonine | TFCHEM (FR) | 2015-11-03 | — | — | US | disclosed |
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | TFCHEM (FR) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | PTMS, SLC5A2, INF2 | CTSL 2599/4885POLB 4428/4885CTSS 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.